Impaired PIEZO1 function in patients with a novel autosomal recessive congenital lymphatic dysplasia

Viktor Lukacs1, Jayanti Mathur2, Rong Mao3,4, Pinar Bayrak-Toydemir3,4, Melinda Procter3, Stuart M. Cahalan1, Helen J. Kim5, Michael Bandell2, Nicola Longo6, Ronald W. Day7, David A. Stevenson6,8, Ardem Patapoutian1 & Bryan L. Krock3,4,9,10

Piezo1 ion channels are mediators of mechanotransduction in several cell types including the vascular endothelium, renal tubular cells and erythrocytes. Gain-of-function mutations in PIEZO1 cause an autosomal dominant haemolytic anaemia in humans called dehydrated hereditary stomatocytosis. However, the phenotypic consequence of PIEZO1 loss of function in humans has not previously been documented. Here we discover a novel role of this channel in the lymphatic system. Through whole-exome sequencing, we identify biallelic mutations in PIEZO1 (a splicing variant leading to early truncation and a non-synonymous missense variant) in a pair of siblings affected with persistent lymphoedema caused by congenital lymphatic dysplasia. Analysis of patients’ erythrocytes as well as studies in a heterologous system reveal greatly attenuated PIEZO1 function in affected alleles. Our results delineate a novel clinical category of PIEZO1-associated hereditary lymphoedema.
The lymphatic system is a network of thin-walled vessels important for extracellular fluid homeostasis. As an important regulator of tissue turgor, development of this network is regulated by interstitial pressure. Lymphatic endothelial cells are also sensitive to shear forces induced by fluid flow, influencing lymphatic valve formation and thereby the function of conducting lymphatic vessels. However, the molecular mechanism of mechanosensation in these cells is largely unknown.

Piezo1 and Piezo2 form a unique class of non-selective cation channels activated by physical stimuli, and are among the few ion channels reliably demonstrated to convey mechanical cues of the environment to mammalian cells. Piezo1 plays an important physiological role in the cardiovascular, renal and haematopoietic systems, while Piezo2 is the principal sensor of mechanical force relevant for touch sensation.

In red blood cells, Piezo1 regulates cell volume homeostasis. Gain-of-function PIEZO1 mutations are linked to cases of dehydrated hereditary stomatocytosis (DHS), a condition of decreased intracellular erythrocyte volume and consequent mild haemolysis. Conversely, blood cell-specific Piezo1 knockout mice exhibit increased erythrocyte size and osmotic fragility. Piezo1 also plays an important role in endothelial shear stress sensing. Systemic loss of Piezo1 function in mice leads to a diminished shear-induced alignment of endothelial cells and a severe impairment of vascular development, leading to embryonic lethality. The full extent to which Piezo1 channels regulate mammalian development and physiology is yet to be elucidated.

In the present study, we describe a novel role for PIEZO1 in the lymphatic system. High-throughput sequencing of a family with a congenital lymphatic dysplasia identified compound heterozygosity for a splicing variant in PIEZO1. Functional analysis of the affected individuals’ red blood cells revealed severely diminished PIEZO1 responses to both mechanical stimuli and the recently characterized pharmacological PIEZO1-activating compound Yoda1. Patch-clamp analysis of the missense PIÉZO1 channel in a heterologous system (a mammalian cell line derived from HEK293T cells) indicated strongly diminished current amplitudes as compared with wild type, likely due to reduced cell surface expression. These findings suggest a role for PIEZO1 in human lymphatic development and implicate it as a novel genetic cause of an autosomal recessive congenital lymphatic dysplasia.

Results

Identification of PIEZO1 variants in congenital lymphoedema patients. A family (Fig. 1a) with a pair of sibs affected with a congenital lymphatic dysplasia was evaluated. II.1 presented at birth with hydrops and bilateral chylothorax, confirmed by fluid analysis. Her neonatal condition was severe, requiring prolonged intensive care including extracorporeal membrane oxygenation. At 42 months of age, she displays significant persistent lymphoedema of her legs, torso and face (Fig. 1b,c), chronic pleural effusions (Fig. 1d), but normal intellectual function. II.2 had minor lymphoedema at birth with swelling of the legs and scrotum. He developed pleural effusions leading to tachypnoea at 3 months of age. Overall, he had a milder clinical course than II.1, but was presumed to have the same genetic condition. Both patients and parents had blood counts including mean corpuscular volume in the normal range. On the basis of these findings, we carried out whole-exome sequencing on the parents as well as the affected sibs. Known genetic causes of congenital lymphoedema were queried, revealing no rare or pathogenic variants. On the basis of the recurrent phenotype in this family, the data were next analysed using a model for autosomal recessive inheritance. Using a population frequency cutoff of <0.1% minor allele frequency based on the 1000 Genomes project, the only candidate gene that fit this mode of inheritance was PIEZO1.

Both affected sibs were compound heterozygotes for a splicing variant, c.3455+1G>A and a missense variant, c.6085G>Cp.Gly2029Arg (Fig. 1e). Neither identified variant has been listed in the publicly available human genomics databases 1000 Genomes, Exome Sequencing Project or the Exome Aggregation Consortium. The c.3455+1G>A variant was inherited from I.1 and the c.6085G>C variant from I.2 (Fig. 1e). c.3455+1G>A alters the canonical splice donor motif of exon 24, and is predicted to result in the inclusion of the 80-base-pair (bp) intron 24 in the mature messenger RNA. Reverse transcription (RT)-PCR and consequent Sanger sequencing of the product confirmed insertion of this intron in all individuals in the family harbouring the c.3455+1G>A variant (Fig. 1f-h–k). This transcript is predicted to encode the peptide p.Ser1153Trpfs*21, a severely truncated product that lacks more than half the protein at the C-terminal end, including the channel pore. The c.6085G>Cp.Gly2029Arg variant alters a highly conserved residue in the PIEZO1 protein (Fig. 1g), which lies immediately adjacent to a predicted transmembrane domain on the presumptive cytoplasmic side in the C-terminal part of the protein. The computational programs SIFT and PolyPhen2 (ref. 20) predict this alteration to be pathogenic. These data, taken together with the involvement of this channel in vascular development, make PIEZO1 a compelling candidate gene for a congenital lymphatic dysplasia.

Strongly decreased function of the identified PIEZO1 variants. We tested whether PIEZO1 function was altered in the affected sibs. It was recently shown that Piezo1 is expressed in murine erythrocytes and that negative pressure pulses applied to the membrane via a tapered-tip glass pipette resulted in calcium influx, that was absent following deletion of Piezo1 (ref. 15). To validate this assay in human erythrocytes, we obtained blood from I.1 and I.2 as well as four additional, unrelated healthy volunteers. Both parental and volunteer erythrocytes exhibited robust calcium entry upon stimulation with negative pressure (Fig. 2a–c,e,f). With the same glass pipettes used for control measurements, pressure-induced calcium responses were not observed in the erythrocytes obtained from I.2 (Fig. 2e,f). Similarly, the recently described Piezo1-activating compound Yoda1 elicited robust calcium entry in control (Fig. 2d,g,h) but not II.1 erythrocytes where it induced only minor calcium responses in a small fraction of the cells (Fig. 2g,h). These results suggest severely decreased PIEZO1 function in the affected individuals.

As erythrocytes from both I.1 and I.2 exhibited relatively normal PIEZO1 responses, we performed a more in-depth analysis of the p.G2029R variant. To enable reliable comparison between the function of this variant and the wild-type PIEZO1 channels, we generated a HEK293T-derived cell line lacking endogenous PIEZO1 (HEK-PIKO, see Methods). Similar to the red blood cells of I.I, HEK-PIKO cells expressing the PIEZO1-G2029R channel displayed a strongly diminished calcium response to Yoda1 as compared with wild type (Fig. 3a). To assess the mechanical responsiveness of PIEZO1-G2029R, we performed whole-cell patch-clamp experiments and stimulated these cells with a blunt glass probe as depicted in the inset in Fig. 3b. The PIEZO1-G2029R channel currents displayed similar current morphology as wild-type channels (Fig. 3b–d), but with greatly decreased average current density (Fig. 3d). While the current responses were strongly diminished in most cells, some...
cells exhibited currents comparable in size to wild type. These results suggested that the p.G2029R mutation may alter PIEZO1 surface expression. The c.3455 + 1G > A variant encodes a severely truncated PIEZO1 protein, which lacks the region shown to contain the pore, and is therefore not expected to be functional.

Missense PIEZO1 variant shows attenuated surface expression in vitro. To test the surface expression of PIEZO1 p.G2029R, we inserted a myc tag at amino-acid position 1,764 in both the wild-type and p.G2029R PIEZO1 channels (P1-eMYC and P1-G2029R-eMYC, respectively). This location is in a predicted extracellular loop in mouse Piezo1, and insertion of a myc tag at this location did not alter channel function. Immunofluorescent labelling of live, unpermeabilized HEK-P1KO cells expressing the same constructs. We found similar fluorescence intensity and percentage of myc-labelled transfected cells in the p.G2029R and wild-type groups, suggesting that both constructs are expressed at comparable levels (Fig. 4b). The reduced surface labelling of cells expressing the P1-G2029R-eMYC channel is in agreement with both our patch-clamp and calcium imaging results, and together suggest that decreased function of PIEZO1-G2029R is, at least to a large extent, due to reduced channel abundance in the plasma membrane.

Discussion
Our data implicate PIEZO1 loss of function as a novel genetic cause of an autosomal recessive congenital lymphatic dysplasia. The affected individuals have a generalized lymphatic dysplasia with some phenotypic overlap with Hennekam syndrome, an autosomal recessive generalized lymphatic dysplasia. However, Hennekam syndrome generally exhibits much more severe lymphoedema, intestinal lymphangiectasia, more severe facial dysmorphisms and intellectual disability. Mild cases of CCBE1-associated Hennekam syndrome have been documented, but these individuals invariably have intestinal lymphangiectasias, which was not observed in the sibs reported herein. The absence of lymphoedema in both parents, the congenital onset and persistent nature of the affected individuals’ lymphoedema and the absence of additional clinical features such as distichiasis, microcephaly, chorioretinopathy,
intellectual disability, hypotrichosis, telangiectasia and lack of mutations in all genes previously associated with other known forms of inherited primary lymphoedema strongly suggest that the symptoms are part of a novel clinical entity termed PIEZO1-associated hereditary lymphoedema.

The affected individuals described are compound heterozygotes for a splicing variant and a single amino-acid substitution. c.3455 +1G>A abolishes a splice donor motif, leading to a frame-shift insertion and a truncated PIEZO1 product that lacks the highly conserved C-terminal region that contains the channel pore\(^{18}\). The other allele contains a single amino-acid change from Gly to Arg at position 2,029. According to recently proposed transmembrane topologies\(^{18}\), this residue is found on a predicted intracellular loop within the aforementioned highly conserved C terminus. It is unlikely that this mutation is directly associated with the ion permeation path, as mutations of acidic residues very closely flanking this location in mouse Piezo1 had no effect on pore properties\(^{18}\). PIEZO1-G2029R channel currents were similar to those in wild type but smaller in maximal amplitude. In rare cases, the amplitude was also comparable to wild type. The
Figure 3 | Attenuated maximal current responses in heterologous cells expressing PIEZO1-G2029R. Wild-type hPIEZO1 and hPIEZO1-G2029R were expressed in HEK-P1KO cells. (a) Fluorescent calcium imaging of cells loaded with Fura-2 expressing PIEZO1 or PIEZO1-G2029R constructs, both containing EGFP driven by an Internal Ribosomal Entry Site for transfection control. Average fluorescence ratios (340 nm/380 nm) of GFP-positive cells are plotted, normalized to baseline ratio values. (b) Representative whole-cell patch-clamp recordings performed using a blunt-ended mechanical probe, which was moved at 1-μm increments to elicit mechanically induced PIEZO1 and PIEZO1-G2029R current responses. A schematic of the measurement configuration is depicted in the inset. Dashed lines indicate zero current levels in the individual traces. A recording of the displacement steps of the mechanical probe is shown above each trace, with the first step that induced visible contact between the probe and the cell depicted in blue colour. Horizontal scale bars, 25 ms, vertical scale bars, 0.1 nA. (c) Current–voltage relationships recorded at the 3rd mechano-elicited response show no differences between wild-type and G2029R channels (n = 5). Insets show representative recordings for wild-type (black) and G2029R (red) channels. Reversal potential was 3.4 ± 1.08 mV and 3.83 ± 0.45 mV for wild-type and G2029R channels, respectively. Horizontal scale bars, 10 ms, vertical scale bars, 0.1 nA. (d) Analysis of mechanically induced current traces shows strongly decreased maximal current densities in the PIEZO1-G2029R channel. Statistics are as compared with the heterologous cells, and may include non-transfected (n = 44). NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9329 | www.nature.com/naturecommunications

residual functional variant in the affected sibs may therefore be a potential candidate for targeted phenotype rescue via chemical chaperonins. Interestingly, a mutation of the nearby residue p.A2020T has the opposite effect; it decreases channel inactivation and is associated with perinatal oedema, which is resolved within a few months after birth23,24. While the lymphoedema persists in the patients described in the present study, the phenotypic similarity raises interesting questions. Piezo1 knockdown in mice is known to perturb alignment of vascular endothelium and therefore inhibit proper blood vessel formation16. It is possible that both increased and decreased sensitivity of lymphatic endothelial cells could result in similar defects in lymphatic vessel development. It is also possible, however, that the mechanism of lymphoedema development in these two cases is unrelated.

We reason that the strongly decreased surface expression in the heterologous system (Fig. 4a) provides an attractive possible molecular mechanism for the loss of PIEZO1 function in II.2 as compared with I.1, who carries one fully functional allele (Fig. 1d,e; Fig. 2a). Decreased surface abundance due to missense mutations has been documented in other channelopathies25,26. However, channel trafficking and regulation may be very different in vivo as compared with the heterologous cells, and may include tissue-specific variability. We therefore cannot rule out other possible mechanisms of action for this mutation. Similarly, we cannot exclude the possibility of alternative splicing resulting in a functional product from the splice variant c.3455 + 1G > A. However, the severely decreased PIEZO1 function in erythrocytes of II.2 argues against the presence of substantial amounts of functional protein produced from this allele. It would be reasonable to hypothesize that the truncated PIEZO1 variant may be dominant negative as part of a multimer subunit complex. The absence of symptoms in parent I.1, however, argue against a major dominant negative effect of this variant.

It is noteworthy that while global deletion of Piezo1 leads to embryonic lethality in mice8,16, our patients exhibit a much milder phenotype despite severely reduced PIEZO1 functionality. It is possible that this is due to residual functional protein, which may be sufficient to maintain vascular development in the patients. It is, however, also possible that this phenotypic difference is due to species differences between mice and humans. Specific ablation of Piezo1 in lymphatic endothelial cells in mice will yield valuable insight into the pathomechanism of this condition on the tissue development level. Furthermore, PIEZO1 functional tests in patients in this novel clinical category will help address the extent of PIEZO1 involvement in human vasculature.
Whole-exome sequencing and analysis show clear surface labelling of 81.5% of the GFP-positive cells in cells unpermeabilized immunofluorescent labelling using an anti-myc antibody. HEK-P1KO cells were transfected with either wild-type P1-eMYC or P1-G2029R-eMYC (Image) Live, unpermeabilized immunofluorescent labelling using an anti-myc antibody show clear surface labelling of 81.5% of the GFP-positive cells in cells expressing P1-eMYC and 17.2% in P1-G2029R-eMYC. Fixed, permeabilized cells were subjected to immunofluorescent labelling with anti-myc and show similar extent of labelling in both wild-type and G2029R groups. Scale bars, 10 μm.

The present study used erythrocytes as reporters of overall PIEZO1 function in the affected individuals, taking advantage of the PIEZO1-dependent calcium responses in these cells. We therefore propose that the novel Piezo1-activating compound Yoda1 serves as a convenient tool to assess PIEZO1 functionality using calcium imaging of red blood cells, a sample that is usually readily obtainable in a clinical setting. This method may serve as a diagnostic or screening tool in future studies.

Methods

Whole-exome sequencing and analysis. Whole-exome sequencing was performed on DNA extracted from whole blood using a previously described method with the following alterations: the Agilent SureSelectXT Human All Exon V4 kit (Agilent Technologies) was used22, and sequencing was performed on the HiSeq2500 instrument (Illumina) with 100-bp paired-end sequencing. The HiSeq2500 instrument was aligned to the human reference genome (Hg19) using Burrow-Wheeler Aligner (0.1.1)23; variants were called with Samtools24 and Genome Analysis Toolkit (v.1.6)25 and annotated with Annovar26. Variants with a quality score <10 were excluded from analysis. Variant filtering and segregation was performed with in-house developed software (https://github.com/brendanofallon/VarViewer). All genes previously associated with congenital lymphoedema (CCBE1, FOXC2, FLI1, KIF11, GATA2, GIC2, SOX18, FAT1 and PTPN14) were specifically analysed and no rare or pathogenic variants were found in any family member despite full exome sequencing. The reported PIEZO1 variants were confirmed by Sanger sequencing using standard methods. Primer sequences are available upon request.

Patient information. II.1 had an extensive clinical and diagnostic evaluation including a single-nucleotide polymorphism chromosomal microarray, lysosomal enzyme panel, screening for congenital disorders of glycosylation, sequencing of the FOXF1 gene and a clinical gene-sequencing panel for Noonan syndrome, all of which was negative. This study was approved by the institutional review boards at the University Of Utah School Of Medicine and the Scripps Research Institute. Informed consent for DNA, RNA and functional analyses and publication of identifying photographs was obtained from study participants in line with institutional review board requirements at the time of collection.

RT-PCR analysis. RNA was extracted from whole blood using a MagNA Pure Compact Instrument (Roche). cDNA was generated from 1 μg total RNA using the SuperScript III First Strand Synthesis kit (Life Technologies) and primed with random hexamers. RT–PCR was performed using the M13-tailed primers (5’-TGT AAAAAAGCGGCGGTACTCCCGACTCAAGTGG-3’ and 5’-CAGGAAAA-CAGCTATGACCTGTAGGTTGATCAAAGCTC-3’) under standard conditions and analysed on a QIAxcel Electrophoresis System (Qiagen). RT–PCR amplifications were Sanger sequenced using M13 primers.

Generation of Piezo1-deficient HEK293T (HEK-PIKO) cells. Piezo1-deficient HEK293T cells were generated using CRISPR/Cas9 nuclease genome engineering. A genomic RNA sequence 5’-TACCTGTGCTGCTGATAGGG-3’ (bases 5,997–5,978 of the hPiezo1 coding sequence, close to the 32nd transmembrane domain) was cloned into a modified version of the plasmid pxPapa9(BB)-2A-GFP27 (D. V. Feng Zhang) in which the coding sequence of enhanced green fluorescent protein (eGFP) was replaced by that of mCherry. HEK293T cells were transfected in six-well plates using 4 μg of plasmid combined with 10 μl of a 1 mg ml⁻¹ solution of PEI Max (Polyscience) in 500 μl OptiMEM (Life Technologies). At 2 days after transfection, cells were dispersed and single fluorescent cells were sorted into individual wells of 24-well plates containing preconditioned complete media using a MoFlo Astrios cell sorter (Beckman Coulter). One clone was identified possessing a homozygous deletion of the sequence 5’-TGCTCCCCC-3’ (bases 5,973–5,980), resulting in a premature truncation of Piezo1. Cells deriving from this clone exhibited no inward cation currents in response to poking, in contrast to parental HEK293T cells that often exhibited high-threshold responses.

Cell culture and electrophysiology. HEK-PIKO cells were cultured in DMEM containing 10% heat-inactivated fetal bovine serum and 1% penicillin/streptomycin (Gibco, Life Sciences). Overexpression of all constructs was achieved with Lipofectamine 2000 according to manufacturer’s instructions (Life Sciences). Whole-cell recordings were conducted using 2–4 MΩ fire-polished borosilicate pipettes forced with a Flaming/Brown P-97 puller (Sutter Instruments). Responses were amplified with an Axopatch 200B differential amplifier, digitized using a Digidata 1,550 multi-channel digitizer, recorded and analysed using the Clampex software suite (Molecular Devices). Recordings were performed in normal extracellular media (NECM) containing (in mM): 140 NaCl, 4 KCl, 1.2 CaCl₂, 2 MgCl₂, 10 HEPES and 10 glucose, pH 7.4. The pipette solution (Cs4A-IC) contained (in mM): 133 CsCl, 7 KCl, 1 CaCl₂, 5 MgCl₂, 4 NaATP, 0.5 NaGTP and 10 HEPES, pH 7.3.

Fluorescent calcium imaging. Erythrocyte calcium imaging experiments were performed as previously described29. Briefly, blood was drawn and stored on ice in EDTA vacutainers. On the experimental day, we diluted whole blood 1:1,000 into NECM supplemented with 0.1% BSA and loaded with 5 μM Fluo-4 at 4°C for at least an hour. Cells were then washed with buffer to remove excess dye and allowed to settle in a custom-build low-volume perfusion chamber, where a gravity-driven whole-chamber perfusion system was used to deliver Yoda1 and the calcium ionophore A23187 after erythrocytes loosely adhered to the uncoated glass-bottom chamber. For mechanical stimulation, we used long, tapered-tip (∼1.5–2 μm diameter) borosilicate pipettes (Sutter instruments, Novato, CA) forced with a Flaming/Brown P-97 puller (Sutter Instruments) and applied negative pressure to the cells using a High-speed Pressure Clamp device (ALC scientific, Farmingdale, NY). Imaging was performed using an Axio Observer (Zeiss) microscope fitted with a Hamamatsu Fura2-AM for 30 min at room temperature in NECM and imaged using the equipment described above.

Materials and constructs. Yoda1 was obtained from the Genomics Institute of the Novartis Research Foundation, commercially available from Maybridge Chemical Company. A23187 was purchased from TOCRIS Bioscience. Point mutations and myc-tagged constructs were generated using Agilent Technologies Chemical Company. A23187 was purchased from TOCRIS Bioscience. Point mutations and myc-tagged constructs were generated using Agilent Technologies chemical company using the Qiagen EmulsiFi Nano Reagent Kit. RT–PCR analysis of RNA extracted from whole blood using a MagNA Pure Compact Instrument (Roche). cDNA was generated from 1 μg total RNA using the SuperScript III First Strand Synthesis kit (Life Technologies) and primed with random hexamers. RT–PCR was performed using the M13-tailed primers (5’-TGT AAAAAAGCGGCGGTACTCCCGACTCAAGTGG-3’ and 5’-CAGGAAAA-CAGCTATGACCTGTAGGTTGATCAAAGCTC-3’) under standard conditions and analysed on a QIAxcel Electrophoresis System (Qiagen). RT–PCR amplifications were Sanger sequenced using M13 primers.

MicroManager imaging software31. Image analysis was performed with FIJI30. HEK-PIKO cells were loaded with 2 μM Fura2-AM for 30 min at room temperature in NECM and imaged using the equipment described above.

Materials and constructs. Yoda1 was obtained from the Genomics Institute of the Novartis Research Foundation, commercially available from Maybridge Chemical Company. A23187 was purchased from TOCRIS Bioscience. Point mutations and myc-tagged constructs were generated using Agilent Technologies chemical company using the Qiagen EmulsiFi Nano Reagent Kit. RT–PCR analysis of RNA extracted from whole blood using a MagNA Pure Compact Instrument (Roche). cDNA was generated from 1 μg total RNA using the SuperScript III First Strand Synthesis kit (Life Technologies) and primed with random hexamers. RT–PCR was performed using the M13-tailed primers (5’-TGT AAAAAAGCGGCGGTACTCCCGACTCAAGTGG-3’ and 5’-CAGGAAAA-CAGCTATGACCTGTAGGTTGATCAAAGCTC-3’) under standard conditions and analysed on a QIAxcel Electrophoresis System (Qiagen). RT–PCR amplifications were Sanger sequenced using M13 primers.

MicroManager imaging software31. Image analysis was performed with FIJI30. HEK-PIKO cells were loaded with 2 μM Fura2-AM for 30 min at room temperature in NECM and imaged using the equipment described above.

Materials and constructs. Yoda1 was obtained from the Genomics Institute of the Novartis Research Foundation, commercially available from Maybridge Chemical Company. A23187 was purchased from TOCRIS Bioscience. Point mutations and myc-tagged constructs were generated using Agilent Technologies chemical company using the Qiagen EmulsiFi Nano Reagent Kit. RT–PCR analysis of RNA extracted from whole blood using a MagNA Pure Compact Instrument (Roche). cDNA was generated from 1 μg total RNA using the SuperScript III First Strand Synthesis kit (Life Technologies) and primed with random hexamers. RT–PCR was performed using the M13-tailed primers (5’-TGT AAAAAAGCGGCGGTACTCCCGACTCAAGTGG-3’ and 5’-CAGGAAAA-CAGCTATGACCTGTAGGTTGATCAAAGCTC-3’) under standard conditions and analysed on a QIAxcel Electrophoresis System (Qiagen). RT–PCR amplifications were Sanger sequenced using M13 primers.

MicroManager imaging software31. Image analysis was performed with FIJI30. HEK-PIKO cells were loaded with 2 μM Fura2-AM for 30 min at room temperature in NECM and imaged using the equipment described above.

Materials and constructs. Yoda1 was obtained from the Genomics Institute of the Novartis Research Foundation, commercially available from Maybridge Chemical Company. A23187 was purchased from TOCRIS Bioscience. Point mutations and myc-tagged constructs were generated using Agilent Technologies chemical company using the Qiagen EmulsiFi Nano Reagent Kit. RT–PCR analysis of RNA extracted from whole blood using a MagNA Pure Compact Instrument (Roche). cDNA was generated from 1 μg total RNA using the SuperScript III First Strand Synthesis kit (Life Technologies) and primed with random hexamers. RT–PCR was performed using the M13-tailed primers (5’-TGT AAAAAAGCGGCGGTACTCCCGACTCAAGTGG-3’ and 5’-CAGGAAAA-CAGCTATGACCTGTAGGTTGATCAAAGCTC-3’) under standard conditions and analysed on a QIAxcel Electrophoresis System (Qiagen). RT–PCR amplifications were Sanger sequenced using M13 primers.
the human MYC13 extracellular tag construct18. The primers used for myc tag insertion were as follows. hPiezo1-Myc1764 (mcy-1fwd): 5’-CAGCTGTTGCTGTCGCAGCCTACTTTCCCGGCC-3’; hPiezo1-Myc1764 (mcy-1rev): 5’-GGGGGGGAAGTAGGCGGCTTGTCAGATCCTTCAGAATAAGTTGTTTGCCTGTAGGCCGACGACACCAGTGG-3’. All generated constructs were verified by full-length cDNA sequencing.

**Immunofluorescent staining.** Live and permeabilized staining of HEK-P1KO cells was carried out as described previously18. Briefly, 24–48 h after transfection cells were permeabilized in PBS containing 0.4% Triton X-100 and blocked with 10% normal goat serum in PBS, fixed with 4% paraformaldehyde/PBS for 10 min, washed five times with PBS, and imaged at an Olympus (Tokyo, Japan) Fluoview 500 confocal microscope by illumination with the HeNe green 543-nm laser. For permeabilized immunostaining, cells were first fixed with 4% paraformaldehyde/PBS for 10 min, washed five times with PBS, permeabilized in PBS containing 0.4% Triton X-100 and blocked with 10% normal goat serum in PBS followed by incubation with antibodies.

**References**

1. Planas-Paz, L. et al. Mechanodinoduction of lymph vessel expansion. *EMBO J.* 31, 788–804 (2012).

2. Sabine, A. et al. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic valve formation. *Dev. Cell* 22, 430–445 (2012).

3. Coste, B. et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. *Science* 330, 55–60 (2010).

4. Coste, B. et al. Piezo proteins are pore-forming subunits of mechanically activated channels. *Nature* 483, 176–181 (2012).

5. Ranade, S. S. et al. Piezo2 is the major transducer of mechanical forces for touch sensation in mice. *Nature* 516, 121–125 (2014).

6. Woo, S. H. et al. Piezo2 is required for Merkel-cell mechanotransduction. *Nature* 509, 622–626 (2014).

7. Coste, B. et al. Gain-of-function mutations in the mechanically activated ion channel PIEZO2 cause a subtype of distal arthrogryposis. *Proc. Natl Acad. Sci. USA* 110, 4667–4672 (2013).

8. Li, J. et al. Piezo1 integration of vascular architecture with physiological force. *Nature* 515, 279–282 (2014).

9. Peyronnet, R. et al. Piezo1-dependent stretch-activated channels are inhibited by Polycystin-2 in renal tubular epithelial cells. *EMBO Rep.* 14, 1143–1148 (2013).

10. Faucherre, A., Kiss, K., Nargeot, J., Mangoni, M. E. & Jopling, C. Piezo1 plays a role in erythrocyte volume homeostasis. *Haematologica* 99, 70–75 (2014).

11. Woo, S. H., Lumpkin, E. A. & Patapoutian, A. Merkel cells and neurons keep in touch. *Trends Cell Biol.* 25, 74–81 (2015).

12. Albuinus, J. et al. Dehydrated hereditary stomatocytosis linked to gain-of-function mutations in mechanically activated PIEZO1 ion channels. *Nat. Commun.* 4, 1884 (2013).

13. Andollo, I. et al. Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1. *Blood* 121, 3925–3935 (2013).

14. Demolombe, S., Duprat, F., Honore, E. & Patel, A. Slower Piezo1 inactivation in dehydrated hereditary stomatocytosis (xerocytosis). *Biophys. J.* 105, 833–844 (2013).

15. Cahalan, S. M. et al. Piezo1 links mechanical forces to red blood cell volume. *Elife* 4, doi:10.7554/eLife.07370 (2015).

16. Ranade, S. S. et al. Piezo1, a mechanically activated ion channel, is required for vascular development in mice. *Proc. Natl Acad. Sci. USA* 111, 10347–10352 (2014).

17. Syeda, R. et al. Chemical activation of the mechanotransduction channel Piezo1. *Elife* 4, doi:10.7554/eLife.07369 (2015).

18. Coste, B. et al. Piezo1 ion channel pore properties are dictated by C-terminal region. *Nat. Commun.* 6, 7223 (2015).

19. Kumar, P., Henkoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat. Protoc.* 4, 1073–1081 (2009).

20. Addzhubei, I. A. et al. A method and server for predicting damaging missense mutations. *Nat. Methods* 7, 248–249 (2010).

21. Alders, M. et al. Mutations in CCR1 cause generalized lymph vessel dysplasia in humans. *Nat. Genet.* 41, 1272–1274 (2009).

22. Frosk, P. et al. A novel CCB1 mutation leading to a mild form of hennekam syndrome: case report and review of the literature. *BMC Med. Genet.* 16, 28 (2015).

23. Grotenboer, S. et al. A genetic syndrome associating dehydrated hereditary stomatocytosis, pseudohyperkalaemia and perinatal oedema. *Br. J. Haematol.* 103, 383–386 (1998).

24. Entemari, M., Becker, R., Menssen, H. D., Marcinkowski, M. & Versmold, H. T. Xerocytosis with concomitant intravascular ascites: first description and therapeutic approach. *Blood* 87, 5392–5393 (1996).

25. Simms, B. A. & Zamponi, G. W. The Brugada syndrome mutation A39V does not affect surface expression of neuronal rat Cav1.2 channels. *Mol. Brain* 5, 9 (2012).

26. Bendahhou, S. et al. Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome. *J. Biol. Chem.* 278, 51779–51785 (2003).

27. Wooldrach-Donahue, W. L. et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. *Am. J. Hum. Genet.* 93, 530–537 (2013).

28. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25, 1754–1760 (2009).

29. Li, H. et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079 (2009).

30. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 20, 1297–1303 (2010).

31. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 38, e164 (2010).

32. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* 8, 2281–2308 (2013).

33. Edelstein, A., Amodaj, N., Hoover, K., Vale, R. & Stuurman, N. *Computer Control of Microscopes Using µManager* (John Wiley & Sons, Inc., 2010).

34. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* 9, 676–682 (2012).

**Acknowledgements**

We thank the patients and their family for their participation in this study. We also thank the clinical genomics laboratory at ARUP for performing whole-exome sequencing. This work was supported by NIH NS083174 to A.P., research awards from The University of Utah Department of Pathology and ARUP Laboratories to B.L.K. S.M.C. is supported by the American Heart Association Grant 14POST2000016. A.P. is a Howard Hughes Medical Institute Investigator.

**Author contributions**

A.P., V.L. and B.L.K. conceived and designed the experiments, analysed the data and wrote the manuscript. D.A.S. evaluated the patients clinically and aided in conception of the study. V.L. and H.J.K. performed electrophysiology. V.L. performed calcium imaging experiments. J.M. generated constructs and performed immunostaining. S.M.C. generated the HEK-P1KO cell line. R.M. and P.B.-T. analysed exome sequencing data and consulted on the study. N.L. and R.W.D. evaluated patients clinically and provided clinical information. M.P. performed RT–PCR and Sanger sequencing. All authors discussed the paper.

**Additional information**

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/